16 completed, 3 terminated, 2 withdrawn, 1 unknown. 22 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 16, Terminated 3, Withdrawn 2, Unknown 1 |
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow lorcaserin: new trials by email Literature Review of lorcaserin trials Research Report on lorcaserin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer Lorcaserin, Lorcaserin Hydrochloride, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2020-11-01 | 2021-01-19 | |
| Rebalancing the Serotonergic System in Cocaine Dependence Lorcaserin, Placebo Oral Tablet - Cocaine Dependence | Phase 1 | Withdrawn | Mclean Hospital | 2018-10-04 | 2025-10-20 | |
| A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima - Healthy Participants | Phase 1 | Completed | Eisai Inc. | 40 | 2018-08-07 | 2018-10-17 |
| Gene-by-Stress Interactions in Intervention Studies Significance Ziprasidone, Lorcaserin, Placebo Oral Tablet - Cardiovascular Diseases | Phase 1 | Terminated | Duke University | 7 | 2018-05-24 | 2020-02-17 |
| Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Lorcaserin, Placebo, Marijuana - Cannabis Use | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 15 | 2017-09-05 | 2022-07-26 |
| Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder Lorcaserin, Placebo - Opioid Abuse, Opioid Dependence | Phase 1 | Completed | Virginia Commonwealth University | 32 | 2017-01-30 | 2020-11-12 |
| Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder lorcaserin, Fitbit Charge HR - Cannabis Use Disorder | Phase 1 | Completed | New York State Psychiatric Institute | 17 | 2016-10-01 | 2019-10-11 |
| Evaluating Muscle Weakness Improvement With Lorcaserin in ICU Lorcaserin, Placebo - Muscle Weakness, Sepsis | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 5 | 2015-12-01 | 2020-01-13 |
| Lorcaserin Intra Venous Cocaine Effects Lorcaserin, 10 mg, Lorcaserin, 20 mg, Oral Placebo - Cocaine Use Disorders | Phase 1 / Phase 2 | Unknown | Midwest Biomedical Research | 32 | 2015-11-01 | 2016-03-18 |
| Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder Lorcaserin, Cocaine Intravenous (IV), Placebo comparator - Cocaine Use Disorder | Phase 1 | Completed | Virginia Commonwealth University | 29 | 2015-07-01 | 2020-05-12 |
| Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder Group A Lorcaserin (10mg), Group A2 Lorcaserin (20 mg), Group B Parallel Placebo - Cocaine-Related Disorders, Opioid-Related Disorders | Phase 1 | Terminated | Virginia Commonwealth University | 171 | 2015-07-01 | 2020-04-27 |
| Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin Lorcaserin, Placebo, Cocaine Infusion - Cocaine Abuse | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 20 | 2015-05-01 | 2017-01-11 |
| A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age Lorcaserin hydrochloride - Obesity | Phase 1 | Completed | Eisai Inc. | 10 | 2015-03-01 | 2015-11-03 |
| A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects APD356 10 mg, APD356 XR-20 mg, APD356 10 mg matching Placebo - Healthy Subjects | Phase 1 | Completed | Eisai Co., Ltd. | 40 | 2014-07-01 | 2016-02-10 |
| Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age Lorcaserin - Pharmacokinetics in Obese Adolescents | Phase 1 | Completed | Eisai Inc. | 8 | 2013-12-01 | 2019-09-17 |
| Lorcaserin for Preventing Weight Gain Among Smokers Varenicline, Lorcaserin - Tobacco Use Disorder, Weight Gain | Phase 1 / Phase 2 | Completed | Mayo Clinic | 20 | 2013-09-01 | 2017-06-06 |
| Pharmacokinetic Study of Belviq in Adult Korean Volunteers Belviq 10mg, Belviq 20mg, Placebo - Healthy | Phase 1 | Completed | IlDong Pharmaceutical Co Ltd | 25 | 2013-06-01 | 2013-10-14 |
| To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake Placebo, Lorcaserin 10mg BID - Obesity | Phase 1 | Completed | Eisai Inc. | 56 | 2008-11-01 | 2019-09-12 |
| Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State Lorcaserin 10mg - Obesity | Phase 1 | Completed | Eisai Inc. | 24 | 2008-11-01 | 2019-09-12 |
| Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects lorcaserin - Obesity | Phase 1 | Completed | Eisai Inc. | 24 | 2008-10-01 | 2023-06-18 |
Showing 20 of 22. Sign in to see all of them.
Obesity (5) · Cocaine-Related Disorders (3) · Opioid-Related Disorders (2) · Cardiovascular Diseases (1) · Muscle Weakness (1) · Renal Insufficiency (1) · Sepsis (1) · Tobacco Use Disorder (1) · Weight Gain (1)
Eisai Inc. (8) · Virginia Commonwealth University (3) · New York State Psychiatric Institute (2) · Duke University (1) · Eisai Co., Ltd. (1) · IlDong Pharmaceutical Co Ltd (1) · Johns Hopkins University (1) · Mayo Clinic (1) · Mclean Hospital (1) · Midwest Biomedical Research (1) · National Institute on Drug Abuse (NIDA) (1) · Ohio State University Comprehensive Cancer Center (1)
United States (19) · Japan (1) · South Korea (1)
Frederick G Moeller, MD (2) · Amy Janes, PhD (1) · Dale M Needham, MD, PhD (1) · Debra Kelsh, Ph.D. (1) · James Bjork, PhD (1) · Kenneth W Grasing, MD (1) · Kyoung Sang You, MD, PhD (1) · Maryam B Lustberg, MD (1) · Ryan Hurt, MD, PhD (1) · William E Kraus, MD (1)
PMID 28365033, PMID 21190985, PMID 24500151, PMID 27852796, PMID 30811963, PMID 39021751
U54DA038999 (3), P01HL036587 (1), P30CA016058 (1), UL1TR001079 (1)